CoChat

Back to the future: Alzheimer's disease heterogeneity revisited

Open access
Au, Rhoda, Piers, Ryan J., Lancashire, Lee · 2015 · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Cited by 45

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

The financial burden of caring for 5.2 million people with Alzheimer's disease (AD) is $214 billion. This number will rise to $1.2 trillion by 2050 if the projected tripling to 16 million cases does occur. Importantly, these estimates are likely to be conservative, given the numerous causes of dementia, underscoring the imperative for treatment. Furthermore, these numbers do not account for the emotional costs to patients and their families. Unfortunately, to date, there are no disease-modifying medications. The presumption of failed clinical trial studies is that intervention may be too late in the course of the disease 1. Thus, current research on AD includes significant effort to identify biomarkers decades before the threshold for clinical diagnosis is met 2. Most current biomarker studies focus on measures of β amyloid (Aβ) detected by positron emission tomography (PET) imaging or measured from cerebrospinal fluid 3-5. However, nearly 75% of cognitively normal individuals aged 70–79 years are free of significant amyloid on PET imaging 6. Furthermore, studies of younger individuals show differences in brain structure and cognitive ability related to APOE genotype status 7 or vascular risk factors 8 at a time when pathologic and in vivo measures of AD pathology are virtually absent. These data suggest that factors other than cerebral amyloidosis during early life may result in increased risk for later-life dementia. There is mounting evidence suggesting a more variable profile in which indices of the neurodegenerative processes (as indicated by changes in cognitive and brain structure) may precede amyloidosis 9. Despite results that challenge the Aβ model for AD pathogenesis, most clinical trial studies remain centered around amyloid as the primary target for drug development 10, 11. We propose that the reason clinical trial studies have largely failed is because the pharmaceutical and AD research communities assume AD is a single disease. In fact, it has been well documented that sporadic AD is a heterogeneous disease 12. Decades ago, the variability of the AD profile and its implication were more widely considered 13-15, but once the NINCDS-ADRDA diagnostic criteria was put into widespread practice, it was largely abandoned. This may be because the definite diagnosis of dementia depends on autopsy data, requiring widespread distribution of amyloid plaques and neurofibrillary tangles for diagnosis 16. Neuropathologic studies, however, suggest that other pathologies often co-occur and at times may lead to antemortem diagnosis of AD, even when neuropathologic criteria are not met 12. Consider now cancer as a model for rethinking the treatment strategy for AD. Like AD, cancer at its end stages is widespread and etiology is difficult to determine. Today, the diagnosis of cancer itself is uninformative. Rather research has determined that there are over 100 different types of cancers, identified in part by symptom variability. As a result of recognizing multiple forms of the disease, drug treatments target each type. Currently, a cancer diagnosis requires additional testing to pinpoint subtype and stage. Depending on the answer, different treatment options are considered. For the diagnosis of leukemia alone, there are over 70 treatment options. For AD, many different drug discovery studies are ongoing but there is no overt strategy of identifying the "types of AD" as potential targets for different drug treatment. Our analogy to cancer is not a clean one. Cancer is a different disease in which biopsy can differentiate between cancer cells and normal ones. The current work on AD biomarkers, however, is an equivalent attempt to find the earliest indicator of disease, similar to detecting preclinical cancer cells. Through biomarker research, the evidence suggests that there are people who are symptomatic for AD that have amyloid and those who do not. Furthermore, there are people without cognitive impairment who have amyloid and those who do not. On commonly used assessment methods, cognitive impairment profiles include those that are predominantly amnestic and those that are not. In fact, for almost every positive study in favor of a particular AD risk factor or biomarker, there are contradictory negative findings. Expression-based classification of patients into groups of interest has been a challenge due to patient heterogeneity. One potential solution to overcome some of these challenges has been to use prior knowledge in the form of information around known signaling pathways or protein-protein interaction networks into the statistical analysis procedure, resulting in a more integrated approach. The activity of these entire pathways or networks is then used, rather than the expression levels of single genes, to stratify patients into their respective groups. It has been shown in a number of studies that these approaches based on utilization of prior knowledge achieve better results (e.g. accuracy, reproduc

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dadm.2015.05.006

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 45

Metadata

Authors
Au, R., Piers, R. J., & Lancashire, L.
Venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher
Wiley
Published
2015-06-27
Volume
1
Issue
3
Pages
368-370
ISSN
2352-8729 (ISSN-L)
OpenAlex
W1496929074
Cited by
45
References
6
FWCI
1.69
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.